The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.
|Videos|June 29, 2017
Dr. Stratigos on the Prevention of Melanoma
Author(s)Alexander J. Stratigos, MD
Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.
Advertisement
Alexander J. Stratigos, MD, University of Athens Medical School, discusses prevention techniques for melanoma.
Primary prevention is an approach that aims to reduce the exposure of UV radiation on human skin. The primary goals are to reduce the exposure through the use of sunscreen and protective clothing, explains Stratigos.
There is also prevention that aims to protect vulnerable populations such as children or outdoor workers. According to Stratigos, it is important for physicians to understand the early clues of skin cancer to better educate their patients on the importance of prevention.
<<<
Advertisement
Related to this article
Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.
VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.
EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.
Experts break down key melanoma data and trends from the 2026 ESMO Congress.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
2
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
3
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
4
Dr Forde on Selecting Neoadjuvant and Perioperative Immunotherapy in Resectable NSCLC
5